

Table S1: Primers used for the construction of plasmids.

Plasmid	Primers for PCR1	Primers for PCR2
pSNVNΔ151-175 pSNVNΔ175-364 pSNVNΔ175-313 pSNVNΔ175-262	Universal primer F1: 5'GATATA CCATGG GCACCCTCAAAGAAGTGC R1=5'AACATATAGATGTCTTTTGATTGTTTGACGGCCCCTAGTG R1=5'CTGAGTACGCCTTAATGGCTTACGTATTCCATTAACCTTCTTC R1=5'TGCTGTAGGTGGACATGGCTTACGTATTCCATTAACCTTCTTC R1=5'TGTTATAAAATAGGCTGGCTTACGTATTCCATTAACCTTCTTC	Universal primer R2: 5'GATATA CCATGG GCACCCTCAAAGAAGTGC F2=5'CGTCAAACAATCAAAGACATCTATATGTTTCTATGCCAACTGCT F2=5'GGAATACGTAAGCCATTAAGGCGTACTCAGTCAATGGGGATTC F2=5'GGAATACGTAAGCCATGTCCACCTACAGCATTATATGTGGCC F2=5'GGAATACGTAAGCCAGCCTATTTTATAACACGTCATTACAG

Constructs: The deletion mutant pSNVNΔ1-50, lacking the N-terminal fifty amino acids was constructed by generating a PCR product from pSNVN plasmid using a forward primer, 5'**CATGCCATGGT**GTCTGCATTGGAGACCAA**ACTCG**3', and reverse primer, 5' **TGGTGGTGCCTCGAG**TTTAAGTGGTTCTTGGTTAGAGATT**TCC**3'. The PCR product was gel purified and digested with Nco I and Xho I restriction enzymes, cloned between the same restriction sites in pTriEx1.1 backbone. The same strategy was used for the construction of all other N terminal deletion mutants, using the same reverse primer and a different forward primer depending upon the type of mutation. The forward primers used for the construction of pSNVNΔ1-100, pSNVNΔ1-150 and pSNVNΔ1-175 were 5' **CATGCCATGGT**TCCTTGATGTAAATTCCATT**GA**CT3', 5' **CATGCCATGG**AAAATAAGGGAACAAGAATCC**G**ATT3', 5' **CATGCCATGG**GACATCTATATGTTTCTATGCCAA**C**3', respectively. The C-terminal deletion mutant pSNVNΔ403-428, expressing N protein lacking twenty six amino acids at the C-terminus was constructed by generating a PCR product from pSNVN plasmid using a forward primer, 5' **CATGCCATGG**GCACCCTCAAAGAAGT**GCAAG**3' and reverse primer 5' **TATAATCTCGAG**ATCCATATCATCTCCAAGAT**GG** 3'. The PCR product was gel purified and digested with NcoI and XhoI and cloned between the same restriction sites in pTriEx1.1 backbone. The same strategy was used for the construction of all the C-terminal deletion mutants, using the same forward primer and different reverse primers, depending upon the type of mutation. The reverse primers used for the construction of pSNVNΔ347-428, pSNVNΔ238-428, pSNVNΔ175-428 and pSNVNΔ163-428 plasmids were 5' **TATAATCTCGAG**AGATTTTGATGCCATTATGG**TG**3', 5' **TATAATCTCGAG**ATCAATCCTTTCCATCCAAT**CT**3', 5' **TATAATCTCGAG**TGGCTTACGTATTCCATTA**ACT**3', 5' **TATAATCTCGAG**ATCATCCTTGAATCGGATT**CTT**3', respectively.

A two-step PCR strategy was used for the construction of plasmids expressing N mutants containing internal deletion. For example, for the construction pSNVNΔ151-175, a PCR product was generated from pSNVN plasmid using a forward universal primer F1: 5' GATATA**CCATGG**GCACCCTCAAAGAAG**TGC**3' and a reverse primer R1: 5'AACATATAGATGTCTTTTGATTGTTTGACGGCCCCTAG**TG**3'. Similarly, a second PCR product was generated from pSNVN plasmid using a forward primer F2: 5'CGTCAAACAATCAAAGACATCTATATGTTTCTATGCCAA**ACTG**CT3', and reverse universal primer R2:

5'TGGTGGTG**CTCGAG**TTTAAGTGGTTCTTGGTTAGAGATTTCCCTGAC3'.

The two PCR products were gel purified and mixed together. The mixture was used as template and a third PCR product was generated using forward universal primer F1 and reverse universal primer R2. This final PCR product was again gel purified, digested with NcoI and XhoI restriction enzymes, cloned between the same restriction sites in pTriEX1.1 backbone. Using this cloning strategy, the mutations were incorporated through forward primer F2 and reverse primer R1. The same strategy was used for the construction of all other plasmids expressing N mutants containing internal deletions (Table S1). In all these constructs the forward universal primer F1 and reverse universal primer R2 were used. However, the sequences of reverse R1 and forward F2 primers were different depending upon the type of mutation (Table S1). The plasmid *pFLuc* was generated by the PCR amplification of the *FLuc* gene from PGL3 vector (Promega) using a forward primer: GCCACCATGGAAGACGCCAAAAACATAAAGA and a reverse primer: AATAACTCGAGCACGGCGATCTTTCCGCCCTTCTTG, containing flanking NcoI and XhoI restriction sites. The PCR product was digested with NcoI and XhoI restriction enzymes and cloned between same sites in pTriEx1.1 backbone (Novagen).